We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 07. | 장 마감 후 (AMC) | $-0.24 | — | — | $0 | — | 예정 |
Consensus PT $13.13 · 8 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 12. | Goldman Sachs | — | 커버리지 개시 | — → Neutral | — | Goldman Sachs: Neutral |
| 2026. 03. 20. | Chardan Capital | — | 의견 유지 | Buy → Buy | — | Chardan Capital: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,871,795 | $10.37B | 0.02% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 471,391 | $2.61B | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Stored first · Google News · Yahoo Finance (English)
Annexon Insider Bought Shares Worth $3,319,019, According to a Recent SEC Filing
Annexon director Muneer Satter buys $3.3m in common stock - Investing.com
Annexon director Muneer Satter buys $3.3m in common stock Investing.com
Annexon director Muneer Satter buys $3.3m in common stock By Investing.com - Investing.com India
Annexon director Muneer Satter buys $3.3m in common stock By Investing.com Investing.com India
Director-linked fund buys 613K Annexon (ANNX) shares in open market - Stock Titan
Director-linked fund buys 613K Annexon (ANNX) shares in open market Stock Titan
Annexon Insider Bought Shares Worth $3,319,019, According to a Recent SEC Filing - Moomoo
Annexon Insider Bought Shares Worth $3,319,019, According to a Recent SEC Filing Moomoo
Annexon to Participate in Upcoming June Investor Conferences - Investing News Network
Annexon to Participate in Upcoming June Investor Conferences Investing News Network